Lotemax

ApprovedSmall molecule

MMedical University of South Carolina

Lotemax is one of 40 small molecule programs targeting Keratoconjunctivitis sicca. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Keratoconjunctivitis SiccaActive, not recruiting

CataractActive, not recruiting

Keratoconjunctivitis SiccaPhase 2

Active, not recruiting

CataractApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Phase 3

6 2

Clobetasol Propionate

Bayer

Phase 3

3 3

Lotemax

MMedical University of South Carolina

Approved

1 4

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Phase 3

1 5

Idose TR

GGlaukos Corporation

Phase 3

1 6

OCS-01

QQuan Dong Nguyen

Phase 3

1 7

XG-102

XXigen SA

Phase 3

2 8

Midalozam

Idorsia Pharmaceuticals Ltd.

Phase 3

2 9

Zolymbus

AbbVie

Preclinical

—10

Neurontin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Randomized1 trial

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Completed·OOphthalmic Consultants of Long Island·Phase 4·NCT00407043·5 enrolled

Graft Versus Host Disease1 trial

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Completed·UUniversity of Michigan·N/A·NCT01695668·75 enrolled

Keratoconjunctivitis sicca1 trial

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Completed·BBausch & Lomb Incorporated·Phase 2·NCT01817582·102 enrolled

Cataract1 trial

Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation

Completed·MMedical University of South Carolina·Phase 4·NCT00366691·40 enrolled

Treatment1 trial

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

Completed·TTufts Medical Center·Phase 4·NCT02120079·37 enrolled

1 more indication

Prednisolone1 trial

Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

Unknown status·IInnovative Medical·Phase 4·NCT01193504·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Lotemax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lotemax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lotemax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedical University of South Carolina

Lotemax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Randomized1 trial

Graft Versus Host Disease1 trial

Keratoconjunctivitis sicca1 trial

Cataract1 trial

Treatment1 trial

Prednisolone1 trial

References

Drug Info

Quick Facts

Related News